Study on the Role of Amritadi Kwath and Trivrittadi Kwath in the Management of Gout (Vatarakta)

A comparative clinical evaluation of amritadi kwath and trivrittadi kwath in the management of vatarakta w.s.r.gout - nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/10/096304

Enrollment

120

Registered

2025-10-22

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E790- Hyperuricemia without signs of inflammatory arthritis and tophaceous disease

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients willing to participate in the trial 2. Patients between the age group of 20 years -65 years. 3. Patients having serum uric acid more then 7mg/dl in males and more then 6mg/dl in females with symptoms of Vatrakta

Exclusion criteria

Exclusion criteria: 1. Patients who do not consent to participate in the trial. 2. Patients below the age of 20 and above 65 years of age. 3. Patients with asymptomatic hyperuricemia and suffering from Secondary gout. 4. Patients suffering from chronic respiratory, cardiac, hepatic, renal and hormonal disorders 5. Pregnancy and lactating mothers.

Design outcomes

Primary

Measure	Time frame
Relief in symptoms like Pain, redness, swelling, stiffness, Burning in Joints, Reduction in serum uric acid levelTimepoint: 30 days	—

Secondary

Measure	Time frame
Reduction in the frequency of attack of vatraktaTimepoint: 30 days	—

Countries

India

Contacts

Public ContactDr. S.D. Pandey

Desh Bhagat University Mandi Gobindgarh

dr.s.d.pandey123@gmail.com9872583155

Outcome results